COMP <GO>
TXMD vs AYTU // EV/EBITDA & P/E VALUATION
TherapeuticsMD Inc. (NASDAQ) VS. Aytu BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: TXMD 1
— AYTU 3
■ METRIC PARITY
LAST: $1.83 (+2.24%) • MKT CAP: $21.2M
valuation
—
LAST: $1.98 (+0.51%) • MKT CAP: $21.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXMD VS. AYTU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXMD | AYTU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 69.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.90% | -35.00% | +22.10 | TXMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.06% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -11.80% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -20.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 1.80% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 5/9 | -3.00 | AYTU | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.3 | 42.0 | -8.68 | AYTU | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.2M | $21.5M | -$338.0K | AYTU | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXMD REV | AYTU REV | TXMD GROSS % | AYTU GROSS % | TXMD FCF | AYTU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $66.4M | — | 69.0% | — | -$2.2M |
| FY 2024 | $1.8M | $65.2M | — | 75.3% | — | -$1.7M |
| FY 2023 | $1.3M | $107.4M | — | — | — | -$5.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXMD // BETA —
AYTU // BETA —